These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3159011)

  • 41. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects.
    Walters JR; Bergstrom DA; Carlson JH; Chase TN; Braun AR
    Science; 1987 May; 236(4802):719-22. PubMed ID: 2953072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors.
    Criswell HE; Mueller RA; Breese GA
    Eur J Pharmacol; 1989 Jan; 159(2):141-7. PubMed ID: 2495973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists.
    Andersen PH; Nielsen EB; Scheel-Krüger J; Jansen JA; Hohlweg R
    Eur J Pharmacol; 1987 Jun; 137(2-3):291-2. PubMed ID: 2956116
    [No Abstract]   [Full Text] [Related]  

  • 44. Differential effects of D1 and D2 dopamine agonists on stereotyped locomotion in rats.
    Eilam D; Clements KV; Szechtman H
    Behav Brain Res; 1991 Nov; 45(2):117-24. PubMed ID: 1686397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation.
    Pifl C; Hornykiewicz O
    Eur J Pharmacol; 1988 Jan; 146(1):189-91. PubMed ID: 3258244
    [No Abstract]   [Full Text] [Related]  

  • 46. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole.
    Zhou LW; Qin ZH; Weiss B
    Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors.
    Koller WC; Herbster G
    Clin Neuropharmacol; 1988 Jun; 11(3):221-31. PubMed ID: 3261198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The dopamine D-1 antagonist SCH 23390 inhibits apomorphine but not pergolide induced rotation.
    Herrera-Marschitz M; Hyttel J; Ungerstedt U
    Acta Physiol Scand; 1984 Nov; 122(3):427-8. PubMed ID: 6240190
    [No Abstract]   [Full Text] [Related]  

  • 49. Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists.
    White FJ; Hu XT; Brooderson RJ
    Eur J Pharmacol; 1990 Dec; 191(3):497-9. PubMed ID: 1982272
    [No Abstract]   [Full Text] [Related]  

  • 50. [Regulation of neural transmission in the mouse vas deferens by 2 subtypes of dopaminergic receptors].
    Mitolo-Chieppa D; Carratù MR; De Serio A; Ferrari E; Conte-Camerino D; Damiani M
    Boll Soc Ital Biol Sper; 1988 Aug; 64(8):763-8. PubMed ID: 2850821
    [No Abstract]   [Full Text] [Related]  

  • 51. Rotation following intranigral injections of a selective D1 or a selective D2 dopamine receptor agonist in rats.
    Asin KE; Montana WE
    Pharmacol Biochem Behav; 1988 Jan; 29(1):89-92. PubMed ID: 3258427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opposing roles of dopamine D1 and D2 receptors in nigral gamma-[3H]aminobutyric acid release?
    Starr M
    J Neurochem; 1987 Oct; 49(4):1042-9. PubMed ID: 2957468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topography of dopamine behaviours mediated by D1 and D2 receptors revealed by intrastriatal injection of SKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Feb; 20(2):589-97. PubMed ID: 2953990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
    Clark D; White FJ
    Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine receptor subtypes and formalin test analgesia.
    Morgan MJ; Franklin KB
    Pharmacol Biochem Behav; 1991 Oct; 40(2):317-22. PubMed ID: 1687167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Specific D1 and D2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat.
    Rouillard C; Bédard PJ
    Neuropharmacology; 1988 Dec; 27(12):1257-64. PubMed ID: 2907616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
    Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
    Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
    Boldry RC; Papa SM; Kask AM; Chase TN
    Brain Res; 1995 Sep; 692(1-2):259-64. PubMed ID: 8548312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B-HT 920 stimulates postsynaptic D2 dopamine receptors in the normal rat: electrophysiological and behavioral evidence.
    Johansen PA; Clarkl D; White FJ
    Life Sci; 1988; 43(6):515-24. PubMed ID: 2900459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
    Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.